Current Opinion in Oncology最新文献

筛选
英文 中文
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer. 免疫检查点抑制剂作为完全切除的非小细胞肺癌癌症患者的辅助治疗。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2024-01-01 Epub Date: 2023-10-20 DOI: 10.1097/CCO.0000000000001003
Robert Pirker
{"title":"Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.","authors":"Robert Pirker","doi":"10.1097/CCO.0000000000001003","DOIUrl":"10.1097/CCO.0000000000001003","url":null,"abstract":"<p><strong>Purpose of review: </strong>The purpose of the review is to summarize the current status of immune checkpoint inhibitors as adjuvant therapy in patients with resected nonsmall cell lung cancer (NSCLC).</p><p><strong>Recent findings: </strong>The IMpower010 phase 3 trial demonstrated improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care among patients with completely resected stage II-IIIA NSCLC. The PEARLS/KEYNOTE-091 trial showed increased disease-free survival for pembrolizumab among patients with stage IB-IIIA NSCLC. Trials with nivolumab and durvalumab are ongoing.</p><p><strong>Summary: </strong>Atezolizumab or pembrolizumab have become options for adjuvant therapy in patients with completely resected NSCLC.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"24-28"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49675389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune checkpoint inhibitors in elderly patients with lung cancer: evidence from phase 3 trials. 免疫检查点抑制剂在老年肺癌患者中的应用:来自3期试验的证据
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2024-01-01 Epub Date: 2023-11-01 DOI: 10.1097/CCO.0000000000001006
Li Wang, Juan Zhou, Xin Yu, Chunxia Su
{"title":"Immune checkpoint inhibitors in elderly patients with lung cancer: evidence from phase 3 trials.","authors":"Li Wang, Juan Zhou, Xin Yu, Chunxia Su","doi":"10.1097/CCO.0000000000001006","DOIUrl":"10.1097/CCO.0000000000001006","url":null,"abstract":"<p><strong>Purpose of review: </strong>In this article, we aimed to summarize the results from recent phase III clinical trials that have evaluated the use of immune checkpoint inhibitors (ICIs) in elderly patients with lung cancer.</p><p><strong>Recent findings: </strong>Lung cancer is the second most diagnosed malignant tumor and the leading cause of cancer-related deaths worldwide. ICIs have a significant role in the treatment of lung cancer, both as monotherapy and combination therapy prolonged survival benefits. At present, a significant proportion of clinical patients comprise individuals aged 70 years or older. However, the inclusion of elderly patients, particularly in clinical trials involving immunotherapy, remains inadequate, with a limited number of participants from this age group. The lack of evidence regarding the use of ICIs in elderly patients is primarily attributed to the significant underrepresentation of elderly individuals in clinical trials.</p><p><strong>Summary: </strong>In this article, we summarize the results from recent phase III clinical trials that have evaluated the use of ICIs as first-line or second-line monotherapy, in combination with chemotherapy and other immunotherapies in elderly patients with lung cancer.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"35-43"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathologic diagnosis of lung cancer - recent developments. 肺癌的病理诊断-最新进展。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2024-01-01 Epub Date: 2023-11-08 DOI: 10.1097/CCO.0000000000001011
Helmut Popper
{"title":"Pathologic diagnosis of lung cancer - recent developments.","authors":"Helmut Popper","doi":"10.1097/CCO.0000000000001011","DOIUrl":"10.1097/CCO.0000000000001011","url":null,"abstract":"<p><strong>Purpose of review: </strong>Diagnosis of lung cancer has previously been based on the evaluation of resection specimen. However, approximately 80% of lung cancers are diagnosed in stage IV. Targeted therapy has changed the practice of pathology. Diagnosis is usually based on small biopsies or even needle aspirations. Subtyping is important, as a molecular classification has to be added.</p><p><strong>Recent findings: </strong>Molecular analysis has to be done in adenocarcinomas and on some of the rarer carcinoma types. Molecular analysis of squamous cell carcinomas should be done in never or former smokers, as they might present with targetable oncogenes. The same applies for adenosquamous carcinomas. Both high-grade neuroendocrine carcinomas should be subtyped. These subtypes might become relevant for new treatment options, currently investigated. Subtyping is done by immunohistochemistry with antibodies for ASCL1, NeuroD1, and POU2F3. In carcinoids, molecular investigation can better define cases with a higher risk of recurrence and metastasis.</p><p><strong>Summary: </strong>Diagnosis of lung cancer is most often done on small biopsies or cytological preparations. Only a minimal number of tissues or cellular material is used for diagnosis. A considerable portion is reserved for molecular analysis. Molecular investigation is important in adenocarcinomas, but also for other rare tumor types.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"57-62"},"PeriodicalIF":3.4,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136396765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schwannomatosis: a Realm Reborn: year one. 神经鞘瘤病:重生境界:第一年。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-09-01 DOI: 10.1097/CCO.0000000000000994
Martin Planet, Michel Kalamarides, Matthieu Peyre
{"title":"Schwannomatosis: a Realm Reborn: year one.","authors":"Martin Planet,&nbsp;Michel Kalamarides,&nbsp;Matthieu Peyre","doi":"10.1097/CCO.0000000000000994","DOIUrl":"10.1097/CCO.0000000000000994","url":null,"abstract":"<p><strong>Purpose of review: </strong>In 2022, an international consensus recommendation revised the nomenclature for neurofibromatosis type 2 ( NF2 ) and Schwannomatosis (SWN), now grouped under the umbrella term Schwannomatosis, and defined new diagnostic criteria.</p><p><strong>Recent findings: </strong>This review describes the molecular criteria for diagnosis of schwannomatosis and the subsequent diagnosis strategy, while setting out the most recent advances in our understanding of the natural history, pathology, molecular biology and treatment of schwannomatosis-associated tumors, including schwannomas, meningiomas and ependymomas.</p><p><strong>Summary: </strong>Somatic mutation screening should become a new standard for the diagnosis of NF2 -, LTZTR1 -, SMARCB1 - and 22q-schwannomatosis to discriminate those conditions. Constitutional events in NF2 -Schwannomatosis have a major influence on disease severity and justifiably motivate ongoing efforts on gene replacement therapy research. On the other hand, underlying mechanisms of disease severity and associated pain remain largely unknown in non- NF2 -SWN and independent of germline mutation. Research efforts therefore focus on pain relief in ongoing trials and the discovery of new molecular mechanisms underlying schwannoma tumorigenesis/pain/neuropathies.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"35 6","pages":"550-557"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy for inflammatory breast cancer: current evidences and future perspectives. 炎症性乳腺癌症的免疫治疗:当前证据和未来展望。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-06-26 DOI: 10.1097/CCO.0000000000000967
Carmine Valenza, Dario Trapani, Giuseppe Curigliano
{"title":"Immunotherapy for inflammatory breast cancer: current evidences and future perspectives.","authors":"Carmine Valenza,&nbsp;Dario Trapani,&nbsp;Giuseppe Curigliano","doi":"10.1097/CCO.0000000000000967","DOIUrl":"10.1097/CCO.0000000000000967","url":null,"abstract":"<p><strong>Purpose of review: </strong>Inflammatory breast cancer (IBC) is the most fatal type presentation of clinical breast cancer. The immune tumor microenvironment (TME) of IBC is characterized by signals of immune evasion but suggests actionable vulnerability to immune-checkpoint inhibitors (ICIs). In this review, we aimed to summarize the most important preclinical evidences of IBC immune-vulnerability and the first data from clinical trials evaluating ICIs in IBC.</p><p><strong>Recent findings: </strong>IBC is characterized by a preexisting active immune TME suppressed by mechanisms of immune-escape, including inhibitory immune-checkpoints, whose expression is higher than in non-IBC. Clinical trials evaluating ICIs in patients with IBC are burdened by slow accrual and low enrollment.</p><p><strong>Summary: </strong>Because of the limited data from clinical trials, no conclusions about the activity of ICIs in IBC can be drawn. Ongoing clinical trials are assessing many promising ICI-based combination approaches. An enhanced multicenter collaboration to evaluate ICIs in patients with this aggressive form of disease and to improve clinical outcomes is required.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"507-512"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer. 基因组特征在早期和转移性癌症三阴性乳腺癌治疗中的临床应用。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-08-21 DOI: 10.1097/CCO.0000000000000989
Grazia Castellano, Federica Giugliano, Giuseppe Curigliano, Antonio Marra
{"title":"Clinical utility of genomic signatures for the management of early and metastatic triple-negative breast cancer.","authors":"Grazia Castellano,&nbsp;Federica Giugliano,&nbsp;Giuseppe Curigliano,&nbsp;Antonio Marra","doi":"10.1097/CCO.0000000000000989","DOIUrl":"10.1097/CCO.0000000000000989","url":null,"abstract":"<p><strong>Purpose of review: </strong>This comprehensive review aims to provide timely and relevant insights into the current therapeutic landscape for triple-negative breast cancer (TNBC) and the molecular features underlying this subtype. It emphasizes the need for more reliable biomarkers to refine prognostication and optimize therapy, considering the aggressive nature of TNBC and its limited targeted treatment options.</p><p><strong>Recent findings: </strong>The review explores the multidisciplinary management of early TNBC, which typically involves systemic chemotherapy, surgery, and radiotherapy. It highlights the emergence of immune checkpoint inhibitors (ICIs), poly(ADP-ribose) polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs) as promising therapeutic strategies for TNBC. Recent clinical trials investigating the use of ICIs in combination with chemotherapy and the approval of pembrolizumab and atezolizumab for PD-L1-positive metastatic TNBC are discussed. The efficacy of PARP inhibitors and ADCs in treating TNBC patients with specific genetic alterations is also highlighted.</p><p><strong>Summary: </strong>The findings discussed in this review have significant implications for clinical practice and research in TNBC. The identification of distinct molecular subtypes through gene expression profiling has enabled a better understanding of TNBC heterogeneity and its clinical implications. This knowledge has the potential to guide treatment decisions, as different subtypes display varying responses to neoadjuvant chemotherapy. Furthermore, the review emphasizes the importance of developing reliable genomic and transcriptomic signatures as biomarkers to refine patient prognostication and optimize therapy selection in TNBC. Integrating these signatures into clinical practice may lead to more personalized treatment approaches, improving outcomes for TNBC patients.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"479-490"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fms -like tyrosine kinase 3 positive acute myeloid leukemia. Fms样酪氨酸激酶3阳性的急性髓系白血病。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-09-05 DOI: 10.1097/CCO.0000000000000993
Alessandro Isidori, Giuseppe Visani, Felicetto Ferrara
{"title":"Fms -like tyrosine kinase 3 positive acute myeloid leukemia.","authors":"Alessandro Isidori,&nbsp;Giuseppe Visani,&nbsp;Felicetto Ferrara","doi":"10.1097/CCO.0000000000000993","DOIUrl":"10.1097/CCO.0000000000000993","url":null,"abstract":"<p><strong>Purpose of review: </strong>Fms -like tyrosine kinase 3 (FLT3) mutations are common in newly diagnosed patients with acute myeloid leukemia (AML). They are associated with a high risk of relapse. The identification of FLT3 mutations has important implications for the management of AML. FLT3 inhibitors have shown improved outcomes in FLT3-positive AML when used as a single agent in the salvage setting. However, the combination of inhibitors and chemotherapy in the first-line setting is the real game changer in FLT3mutant AML. The introduction of these drugs has improved the prognosis of FLT3-mutant AML, but the development of resistance is common. There are still many unanswered questions about FLT3-mutant AML.</p><p><strong>Recent findings: </strong>This article will analyze recent advances for FLT3-mutant AML, focusing on front-line therapy and post-transplant maintenance.</p><p><strong>Summary: </strong>Novel drug combinations and strategies against FLT3 mutated AML are currently under investigation and will be the focus of future studies. The development of more selective and potent FLT3 inhibitors may further improve outcomes for patients with FLT3-positive AML. Monitoring minimal residual disease and overcoming resistance are key issues for the future.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"35 6","pages":"589-593"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurable residual disease in peripheral blood in myeloma: dream or reality. 骨髓瘤患者外周血中可测量的残余疾病:梦想还是现实。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-08-13 DOI: 10.1097/CCO.0000000000000987
Tadeusz Kubicki, Benjamin A Derman, Dominik Dytfeld, Andrzej J Jakubowiak
{"title":"Measurable residual disease in peripheral blood in myeloma: dream or reality.","authors":"Tadeusz Kubicki,&nbsp;Benjamin A Derman,&nbsp;Dominik Dytfeld,&nbsp;Andrzej J Jakubowiak","doi":"10.1097/CCO.0000000000000987","DOIUrl":"10.1097/CCO.0000000000000987","url":null,"abstract":"<p><strong>Purpose of review: </strong>Therapeutic advancements in multiple myeloma have led to increasingly deeper and more durable responses, creating a need for highly sensitive and applicable techniques for measurable residual disease (MRD) assessment. Bone marrow assays can deeply assess for MRD, but it is not conducive to performing frequent and dynamic evaluations, which may be needed for MRD-adapted treatment approaches. Recently, numerous techniques for MRD assessment in peripheral blood have come under investigation, and their integration into routine clinical practice is eagerly anticipated.</p><p><strong>Recent findings: </strong>The identification of circulating tumor cells (CTCs), evaluation of cell-free DNA, and measuring monoclonal protein concentration with mass spectrometry are promising research areas for assessing myeloma in peripheral blood. CTCs assessment and cell-free DNA may carry prognostic significance, but they lack the sensitivity of bone marrow-based techniques. Mass spectrometry has already been implemented in clinical practice in certain centers, but its full potential has yet to be fully realized. This review focuses on recent developments in these fields, emphasizing the potential future roles of these assessments.</p><p><strong>Summary: </strong>MRD assessment in peripheral blood is still in the development stage but holds promise for not only complementing bone marrow based evaluations but also potential for improving sensitivity.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"574-580"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent advances in allogeneic transplantation for acute myeloid leukemia. 异基因移植治疗急性髓系白血病的最新进展。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-08-30 DOI: 10.1097/CCO.0000000000000992
Juan Montoro, Aitana Balaguer-Roselló, Jaime Sanz
{"title":"Recent advances in allogeneic transplantation for acute myeloid leukemia.","authors":"Juan Montoro,&nbsp;Aitana Balaguer-Roselló,&nbsp;Jaime Sanz","doi":"10.1097/CCO.0000000000000992","DOIUrl":"10.1097/CCO.0000000000000992","url":null,"abstract":"<p><strong>Purpose of review: </strong>This review highlights recent advancements in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with acute myeloid leukemia (AML).</p><p><strong>Recent findings: </strong>Important improvements have been observed throughout the allo-HSCT procedure and patient management. Universal donor availability and reduced risk of graft-versus-host disease (GVHD) have been achieved with the introduction of posttransplant cyclophosphamide for GVHD prophylaxis. It has contributed, together with advances in conditioning regimens, GVHD treatment and supportive care, to a reduced overall toxicity of the procedure. Relapse is now the most frequent cause of transplant failure. With increased knowledge of the biological characterization of AML, better prediction of transplant risks and more profound and standardized minimal residual disease (MRD) monitoring, pharmacological, and immunological strategies to prevent relapse are been developed.</p><p><strong>Summary: </strong>Allo-HSCT remains the standard of care for high-risk AML. Increased access to transplant, reduced toxicity and relapse are improving patient outcomes. Further research is needed to optimize MRD monitoring, refine conditioning regimens, and explore new GVHD management and relapse prevention therapies.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":"35 6","pages":"564-573"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer. 模拟禁食饮食:一种治疗癌症的代谢方法。
IF 3.4 4区 医学
Current Opinion in Oncology Pub Date : 2023-11-01 Epub Date: 2023-07-28 DOI: 10.1097/CCO.0000000000000986
Francesca Ligorio, Leonardo Provenzano, Claudio Vernieri
{"title":"Fasting-mimicking diet: a metabolic approach for the treatment of breast cancer.","authors":"Francesca Ligorio,&nbsp;Leonardo Provenzano,&nbsp;Claudio Vernieri","doi":"10.1097/CCO.0000000000000986","DOIUrl":"10.1097/CCO.0000000000000986","url":null,"abstract":"<p><strong>Purpose of review: </strong>Metabolic reprogramming is a new and potentially targetable hallmark of cancer. In recent years, fasting and fasting-mimicking diets (FMDs) have been tested as anticancer strategies both in preclinical experiments and in clinical trials. In this review, we aim at summarizing the available evidence about the antitumour activity of these approaches in preclinical breast cancer models, as well as results from clinical trials investigating fasting/FMD in breast cancer patients.</p><p><strong>Recent findings: </strong>Preclinical evidence demonstrated that nutrient deprivation boosts the antitumor activity of chemotherapy, immunotherapy or targeted therapies in triple-negative breast cancer (TNBC) and HR+/HER2 models through both cell-autonomous antitumour effects in cancer cells and favourable modifications in intratumor immune cells. Several clinical experiences demonstrated that fasting/FMD is feasible and well tolerated in combination with standard treatments in BC patients, and that it could reduce chemotherapy-related toxicities. Finally, despite the absence of randomized trials demonstrating the antitumor activity of fasting/FMD in breast cancer patients, preliminary clinical reports suggest that this experimental nutritional strategy may enhance chemotherapy activity. Randomized clinical trials are ongoing to validate these results at a larger scale.</p><p><strong>Summary: </strong>Fasting/FMD is a promising therapeutic approach in patients with breast cancer; ongoing and future trials will confirm their role in improving breast cancer care.</p>","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"491-499"},"PeriodicalIF":3.4,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10067714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信